AI-powered bioinformatics startup Proscia has entered a partnership with AI-driven biotech unicorn company Owkin to advance pathology from drug discovery to diagnostics.

The collaboration will enable Owkin to join Proscia's Ready partner alliance, a collective of solution providers that assist labs and life science firms in implementing AI-enabled digital pathology on a massive scale. The company also plans to develop and commercialize AI solutions for research and diagnosis, which could be incorporated into Proscia's Concentriq precision medicine AI portfolio. The shared focus of the partnership is on advancing pathology for novel therapies and treatment decisions to enhance the potential impact of AI in medicine. 

Analyst QuickTake: In October 2024 , Proscia introduced the Concentriq Embeddings to its Concentriq platform and the Proscia AI toolkit to speed up AI use in pathology and aid the development of diagnostic procedures and drug discovery. The Embeddings facilitates the conversion of whole slide images into numerical representations, and the AI Toolkit was designed to provide developers with open-source resources to design and implement AI solutions.